Risk factors and severity of melasma in patients attending dermatology outpatient department of a tertiary care hospital: A cross-sectional study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
ppublish
Résumé
Melasma is a chronic acquired dysfunction of melanogenesis characterized by dark brown irregular macules on skin. Genetic predisposition, pregnancy, sun exposure, and hormonal therapy are common risk factors. Prevalence of melasma is variable, ranging from 5% to 46%. This study aimed to assess the severity and potential risk factors of melasma in a tertiary care setting. An analytical cross-sectional study was conducted on patients with melasma visiting dermatology department of a tertiary care center in Nepal. Nonprobability consecutive sampling was adopted. Severity of melasma was assessed using the Modified Melasma Area and Severity Index score. Data analysis was performed using the Statistical Package for the Social Sciences, version-23. Bivariate analysis was done by using Student t test/Mann-Whitney U test, or Chi-square/Fischer exact test for continuous and categorical variables, respectively. The overall median Modified Melasma Area and Severity Index score was 5.40 (3.60-6.75). Most patients (168, 88.42%) had mild melasma. The severity score was significantly higher in older age (P = .024), women having parity more than 3 (P = .014), centrofacial pattern (P = .024), and patients having dermatological comorbidities (P = .014). Severity was significantly lower in those who used cosmetics at home. Moreover, the use of digital screens was not associated with an increase in melasma severity. Most of the cases had mild melasma. Severity was significantly associated with age, parity, pattern, practice of cosmetic use, and presence of dermatological comorbidities.
Identifiants
pubmed: 39287320
doi: 10.1097/MD.0000000000039674
pii: 00005792-202409130-00098
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e39674Informations de copyright
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Handel AC, Miot LDB, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014;89:771–82.
Ortonne J, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254–62.
Vázquez M, Maldonado H, Benmamán C, Sanchez JL. Melasma in men. Int J Dermatol. 1988;27:25–7.
Perez M, Sanchez JL, Aguilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983;81:543–5.
Demirkan S, Gündüz O, Sayan CD. Retrospective analysis of endemic melasma patients. Dermatol Reports. 2017;9:31–3.
Guinot C, Cheffai S, Latreille J, et al. Aggravating factors for melasma: a prospective study in 197 Tunisian patients. J Eur Acad Dermatol Venereol. 2010;24:1060–9.
Moin A, Jabery Z, Fallah N. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45:285–8.
Hexsel D, Lacerda DA, Cavalcante AS, et al. Epidemiology of melasma in Brazilian patients: a multicenter study. Int J Dermatol. 2014;53:440–4.
Shenoi SD, Davis SV, Rao S, Rao G, Nair S. Dermatoses among paddy field workers—a descriptive, cross-sectional pilot study. Indian J Dermatol Venereol Leprol. 2005;71:254–8.
Rodrigues M, Ayala-Cortés AS, Rodríguez-Arámbula A, Hynan LS, Pandya AG. Interpretability of the Modified Melasma Area and Severity Index (mMASI). JAMA Dermatol. 2016;152:1051–2.
KrupaShankar DSR, Somani VK, Kohli M, et al. A cross-sectional, multicentric clinico-epidemiological study of melasma in India. Dermatol Ther (Heidelb). 2014;4:71–81.
Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56:380–2.
Yalamanchili R, Shastry V, Betkerur J. Clinico-epidemiological study and quality of life assessment in melasma. Indian J Dermatol. 2015;60:519.
Kothari P, Sharma YK, Patvekar MA, Gupta A. Correlating impairment of quality of life and severity of melasma: a cross-sectional study of 141 patients. Indian J Dermatol. 2018;63:292–6.
Sarkar R, Jagadeesan S, Basavapura Madegowda S, et al. Clinical and epidemiologic features of melasma: a multicentric cross-sectional study from India. Int J Dermatol. 2019;58:1305–10.
Morgaonkar M, Gupta S, Vijay A, Jain SK, Sharma M, Agarwal S. Melasma: its impact on quality of life. Pigment Int. 2017;4:39.
Austin E, Huang A, Adar T, Wang E, Jagdeo J. Electronic device generated light increases reactive oxygen species in human fibroblasts. Lasers Surg Med. 2018;50:689–95.
Searle T, Al-Niaimi F, Ali FR. Screen light and the skin. Clin Exp Dermatol. 2021;46:934–5.
Jaulim SZ, Yoo J. Does high-energy visible light emitted from electronic devices cause melasma? Clin Exp Dermatol. 2021;46:922–3.
Duteil L, Queille-Roussel C, Lacour JP, Montaudié H, Passeron T. Short-term exposure to blue light emitted by electronic devices does not worsen melasma. J Am Acad Dermatol. 2020;83:913–4.